Selpercatinib / Medullary Thyroid Cancer / Solid Tumor · Phase 2 Trial

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

ClinicalTrials.gov · August 7, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 2 trial of selpercatinib in RET-driven solid tumors conducted in China, currently active but not recruiting. No efficacy or safety results are reported in this registry record; the study remains in progress.

What was studied

Phase 2, Interventional, Single Group, Open label, Treatment purpose. Solid Tumor, Medullary Thyroid Cancer; age from 18 Years. Intervention: Selpercatinib. n = 77. 13 sites: China.

Key findings

Safety

No efficacy or safety results are posted in this registry record.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

Phase 2 interventional trial in an active but unrecruitment stage with no results reported in this registry record; design and endpoints are specified but outcome data are absent.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) (assessed at Date of First Dose to Disease Progression or Death (up to 12 Months)); Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC (assessed at Date of First Dose to Disease Progression or Death (Up to 12 months))

DesignPhase 2, Interventional, Single Group, Open label, Treatment purpose

PopulationSolid Tumor, Medullary Thyroid Cancer; age from 18 Years

Sample size77

InterventionSelpercatinib

Setting13 sites: China

Reported figures

Quoted from the source exactly as published.

Planned enrollment77

PhasePHASE2

Primary endpoint (Primary Analysis Set)Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)

Primary endpoint (Primary Analysis Set)Date of First Dose to Disease Progression or Death (up to 12 Months)

Caveats

No efficacy or safety results are posted in this registry record.
Trial status is active but not recruiting; final data are not yet available.
Recruitment status and enrollment completeness do not indicate data maturity or readiness for analysis.
Blinding status, randomization method, and detailed eligibility criteria are not stated in this registry record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 2 interventional design with independent review committee assessment planned.

Directness

strong

Direct evaluation of selpercatinib efficacy and safety in target populations: RET fusion-positive tumors, medullary thyroid cancer, RET-activated tumors.

Consistency

insufficient

No results reported; consistency cannot be assessed from registry record alone.

Risk of bias

moderate

Independent review committee for response assessment reduces detection bias; blinding status not reported.

Sample adequacy

limited

Actual enrollment 77 participants across multiple tumor types; small for Phase 2 comparisons.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT04280081). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 77 participants (ACTUAL). Conditions: Solid Tumor, Medullary Thyroid Cancer. Interventions: DRUG: Selpercatinib. Primary outcome measures: Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) , Date of First Dose to Disease Progression or Death (up to 12 Months); Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC , Date of First Dose to Disease Progression or Death (Up to 12 months). Brief summary: The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Eli Lilly and CompanyNCT04280081SelpercatinibMedullary Thyroid CancerSolid Tumor